NYSE:ZYME - Zymeworks Stock Price, Forecast & News

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Zymeworks Inc (NYSE:ZYME) posted its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.76) by $0.06. The firm earned $7.86 million during the quarter, compared to the consensus estimate of $7.77 million. Zymeworks had a negative return on equity of 25.72% and a negative net margin of 112.95%. View Zymeworks' Earnings History.

Zymeworks is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Zymeworks.

11 analysts have issued 12 month price objectives for Zymeworks' shares. Their forecasts range from $23.00 to $70.00. On average, they anticipate Zymeworks' stock price to reach $48.55 in the next twelve months. This suggests a possible upside of 15.2% from the stock's current price. View Analyst Price Targets for Zymeworks.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zymeworks.

Media headlines about ZYME stock have been trending negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zymeworks earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days. View News Stories for Zymeworks.

Zymeworks saw a increase in short interest in January. As of January 31st, there was short interest totalling 842,500 shares, an increase of 59.2% from the January 15th total of 529,100 shares. Based on an average daily trading volume, of 443,500 shares, the days-to-cover ratio is presently 1.9 days. Currently, 2.7% of the company's stock are short sold. View Zymeworks' Current Options Chain.

Some companies that are related to Zymeworks include ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH) and Mirati Therapeutics (MRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Just Energy Group (JE), Just Energy Group (JE), Cronos Group (CRON), Advanced Micro Devices (AMD), Sangamo Therapeutics (SGMO), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Immunomedics (IMMU), Viking Therapeutics (VKTX) and Aurora Cannabis (ACB).

(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

Zymeworks' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (7.50%), Perceptive Advisors LLC (6.10%), Farallon Capital Management LLC (4.32%), FIL Ltd (4.10%), Franklin Resources Inc. (1.49%) and Marshall Wace North America L.P. (1.42%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly, Neil A Klompas and Troy Cox. View Institutional Ownership Trends for Zymeworks.

ZYME stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Sofinnova Investments Inc., Franklin Resources Inc., Oxford Asset Management LLP, Vident Investment Advisory LLC, Farallon Capital Management LLC, Raymond James & Associates and UBS Group AG. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, David Kai Yuen Poon and Neil A Klompas. View Insider Buying and Selling for Zymeworks.

ZYME stock was acquired by a variety of institutional investors in the last quarter, including FIL Ltd, Marshall Wace North America L.P., Samlyn Capital LLC, Candriam Luxembourg S.C.A., UBS Asset Management Americas Inc., Renaissance Technologies LLC, Picton Mahoney Asset Management and Credit Suisse AG. View Insider Buying and Selling for Zymeworks.

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZYME stock can currently be purchased for approximately $42.15.

Zymeworks has a market capitalization of $1.66 billion and generates $53.02 million in revenue each year. The company earns $-36,560,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Zymeworks employs 180 workers across the globe.View Additional Information About Zymeworks.

The official website for Zymeworks is http://www.zymeworks.com/.

Zymeworks' mailing address is 540-1385 WEST 8TH AVENUE, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]